Gene and Oncogene Targeting Team Publications

Team Leader: Professor Caroline Springer

Location: Haddow Laboratories, Sutton

Section: Cancer Research UK Cancer Therapeutics Unit

Publications

Menard D, Niculescu-Duvaz I, Dijkstra HP, Niculescu-Duvaz D, Suijkerbuijk BMJM, Zambon A, Nourry A, Roman E, Davies L, Marine HA, Friedlos F, Kirk R, Whittaker S, Gill A, Taylor RD, Marais R, Springer CJ. Novel potent BRAF inhibitors: Toward 1nM compounds through optimization of the central phenyl ring. J Med Chem 52:3881-91, 2009

Mancini L, Davies L, Friedlos F, Falck-Miniotis M, Dzik-Jurasz AS, Springer CJ, Leach MO, Payne GS. A novel technique to monitor carboxypeptidase G2 expression in suicide gene therapy using F-19 magnetic resonance spectroscopy. NMR in Biomed 22:561-6, 2009

Niculescu-Duvaz D, Gaulon C, Dijkstra HP, Niculescu-Duvaz I, Zambon A, Menard D, Suijkerbuijk BMJM, Nourry A, Davies L, Manne H, Friedlos F, Ogilvie L, Hedley D, Whittaker S, Kirk R, Gill A, Taylor RD, Raynaud FI, Moreno-Farre J, Marais R, Springer CJ. Pyridoimidazolones as novel potent inhibitors of v-Raf murine sarcoma viral oncogene homologue B1 (BRAF). J Med Chem 52:2255-64, 2009

Friedlos F, Lehouritis P, Ogilvie L, Hedley D, Davies L, Bermudes D, King I, Martin J, Marais R, Springer CJ. Attenuated Salmonella targets prodrug activating enzyme carboxypeptidase G2 to mouse melanoma and human breast and colon carcinomas for effective suicide gene therapy. Clin Cancer Res 14:4259-66, 2008

Niculescu-Duvaz I, Roman E, Whittaker SR, Friedlos F, Kirk R, Scanlon IJ, Davies LC, Niculescu-Duvaz D, Marais R, Springer CJ. Novel inhibitors of the v-raf murine sarcoma viral oncogene homologue B1 (BRAF) based on a 2,6-disubstituted pyrazine scaffold. J Med Chem 51:3261-74, 2008

Schepelmann S, Ogilvie LM, Hedley D, Friedlos F, Martin J, Scanlon I, Chen P, Marais R, Springer CJ. Suicide gene therapy of human colon carcinoma xenografts using an armed oncolytic adenovirus expressing carboxypeptidase G2. Cancer Res 67: 4949-55, 2007

Hedley D, Ogilvie L, Springer CJ. Carboxypeptidase G2-based gene-directed enzyme–prodrug therapy: a new weapon in the GDEPT armoury. Nat Rev Cancer 7:870-87, 2007

Schepelmann S, Hallenbeck P, Ogilvie LM, Hedley D, Friedlos F, Martin J, Scanlon I, Hay C, Hawkins LK, Marais R, Springer CJ. Systemic gene-directed enzyme prodrug therapy of hepatocellular carcinoma using a targeted adenovirus armed with carboxypeptidase G2. Cancer Res 65:5003-8, 2005

Friedlos F, Davies L, Scanlon I, Ogilvie LM, Martin J, Stribbling SM, Spooner RA, Niculescu-Duvaz I, Marais R, Springer CJ. Three new prodrugs for suicide gene therapy using carboxypeptidase G2 elicit bystander efficacy in two xenograft models. Cancer Res 62:1724-9, 2002

Niculescu-Duvaz I, Roman E, Whittaker SR, Friedlos F, Kirk R, Scanlon IJ, Davies LC, Niculescu-Duvaz D, Marais R, Springer CJ. Novel inhibitors of B-RAF based on a disubstituted pyrazine scaffold. Generation of a nanomolar lead. J Med Chem 49:407-16, 2006

View more publications from Professor Caroline Springer.